LAEKNA-B (02105) Completes First Patient Dosing in Phase I Single Ascending Dose Study for LAE103

Stock News2025-12-31

LAEKNA-B (02105) announced that the group has commenced patient enrollment for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia.

As of the date of this announcement, the first subject has completed dosing.

This SAD study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE103 (administered subcutaneously) in healthy subjects who are overweight or have obesity.

The group aims to announce the topline data from this SAD study in the third quarter of 2026.

The group is committed to introducing this precision therapy into areas of cardiovascular and metabolic diseases with significant unmet medical needs, such as obesity, sarcopenia, and heart failure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100137130?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 08:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100137130","market":"us","top_or_hot":-1,"title":"LAEKNA-B (02105) Completes First Patient Dosing in Phase I Single Ascending Dose Study for LAE103","media":"Stock News","content":"<p>LAEKNA-B (02105) announced that the group has commenced patient enrollment for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia.</p>\n<p>As of the date of this announcement, the first subject has completed dosing.</p>\n<p>This SAD study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE103 (administered subcutaneously) in healthy subjects who are overweight or have obesity.</p>\n<p>The group aims to announce the topline data from this SAD study in the third quarter of 2026.</p>\n<p>The group is committed to introducing this precision therapy into areas of cardiovascular and metabolic diseases with significant unmet medical needs, such as obesity, sarcopenia, and heart failure.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAEKNA-B (02105) Completes First Patient Dosing in Phase I Single Ascending Dose Study for LAE103</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAEKNA-B (02105) Completes First Patient Dosing in Phase I Single Ascending Dose Study for LAE103\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-31 08:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LAEKNA-B (02105) announced that the group has commenced patient enrollment for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia.</p>\n<p>As of the date of this announcement, the first subject has completed dosing.</p>\n<p>This SAD study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE103 (administered subcutaneously) in healthy subjects who are overweight or have obesity.</p>\n<p>The group aims to announce the topline data from this SAD study in the third quarter of 2026.</p>\n<p>The group is committed to introducing this precision therapy into areas of cardiovascular and metabolic diseases with significant unmet medical needs, such as obesity, sarcopenia, and heart failure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1100137130","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100137130","pubTimestamp":1767141623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LAEKNA-B (02105) announced that the group has commenced patient enrollment for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia. As...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02105":"来凯医药-B"},"translate_title":"LAEKNA-B(02105)完成LAE103 I期单次递增剂量研究的首例患者给药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"LAEKNA-B (02105) announced that the group has commenced patient enrollment for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia.\nAs of the date of this announcement, the first subject has completed dosing.\nThis SAD study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE103 (administered subcutaneously) in healthy subjects who are overweight or have obesity.\nThe group aims to announce the topline data from this SAD study in the third quarter of 2026.\nThe group is committed to introducing this precision therapy into areas of cardiovascular and metabolic diseases with significant unmet medical needs, such as obesity, sarcopenia, and heart failure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100137130","isCrawlerRequest":true}